• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
78,180.72 -104.35
( -0.13%)
Global Indices
Nasdaq
53,071.47 150.40
(0.28%)
Dow Jones
7,557.54 53.30
(0.71%)
Hang Seng
68,399.59 -1,338.10
(-1.92%)
Nikkei 225
10,649.07 -29.96
(-0.28%)
Forex
USD-INR
95.19 -0.09
(-0.09%)
EUR-INR
108.86 0.10
(0.10%)
GBP-INR
127.02 0.03
(0.03%)
JPY-INR
0.59 0.00
(-0.02%)

EQUITY - MARKET SCREENER

Orbit Exports Ltd
Industry :  Textiles - Processing
BSE Code
ISIN Demat
Book Value()
512626
INE231G01010
106.5895409
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ORBTEXP
19.6
610.42
EPS(TTM)
Face Value()
Div & Yield %
11.75
10
0
 

Aurobindo Pharma's API unit clears USFDA inspection with two observations
Jun 29,2026
The inspection, conducted between 22 June and 26 June 2026, covered the facility that manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates.

The inspection concluded with two observations. The company said it will respond to the observations within the stipulated timeline.

Aurobindo Pharma reiterated its commitment to maintaining the highest quality manufacturing standards and said it will keep the stock exchanges informed of any further developments related to the inspection.

The official announcement was made on Saturday, 27 June 2026.

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.

The counter advanced 1.15% to Rs 1,572.85 on the BSE.